An emerging toolkit for targeted cancer therapies

Genome Research

Volumn 22, Issue 2, 2012, Pages 177-182

  Mills, Gordon B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH; CANCER PATIENT; CANCER THERAPY; DNA METHYLATION; DNA SEQUENCE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; NOTE; PRIORITY JOURNAL; RNA EDITING; RNA SPLICING;

GENE REGULATORY NETWORKS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; TECHNOLOGY; TUMOR MARKERS, BIOLOGICAL;

EID: 84856555469     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.136044.111     Document Type: Note

References (45)

1. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, et al. 2007. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402. (Pubitemid 47539306)
2. Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, Chen S, Karchin R, Kinzler KW, Vogelstein B, Nowak MA. 2010. Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci 107: 18545-18550.
3. Brooks JD. 2012. Translational genomics: The challenge of developing cancer biomarkers. Genome Res (this issue). doi: 10.1101/gr.124347.111.
4. Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
5. Cancer Genome Atlas Research Network. 2011. Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
6. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, et al. 2011. KIT as a therapeutic target in metastatic melanoma. JAMA 305: 2327-2334.
7. Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, Barnes R, Watson P, Allen-Vercoe E, Moore RA, et al. 2012. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res (this issue). doi: 10.1101/gr.126516.111.
8. Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Zhang F, Ju Z, et al. 2011. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 1: 170-185.
9. Chin L, Hahn WC, Getz G, Meyerson M. 2011. Making sense of cancer genomic data. Genes Dev 25: 534-555.
10. Ciriello G, Cerami E, Sander C, Schultz N. 2012. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res (this issue). doi: 10.1101/gr.125567.111.
11. Dewal N, Hu Y, Freedman ML, Laframboise T, Pe'er I. 2012. Calling amplified haplotypes in next generation tumor sequence data. Genome Res (this issue). doi: 10.1101/gr.122564.111.
12. Druker BJ. 2008. Translation of the Philadelphia chromosome into therapy for CML. Blood 112: 4808-4817.
13. Gerber DE, Minna JD. 2010. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 18: 548-551.
14. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, et al. 2011. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancers. Mol Can Ther 10: 1093-1101.
15. Greenman CD, Pleasance ED, Newman S, Yang F, Fu B, Nik-Zainal S, Jones D, Lau KW, Carter N, Edwards PA, et al. 2012. Estimation of rearrangement phylogeny for cancer genomes. Genome Res (this issue). doi: 10.1101/gr.118414. 110.
16. Guenthoer J, Diede SJ, Tanaka H, Chai X, Hsu L, Tapscott SJ, Porter PL. 2012. Assessment of palindromes as platforms for DNA amplification in breast cancer. Genome Res (this issue). doi: 10.1101/gr.117226.110.
17. Harris TJ, McCormick F. 2010. The molecular pathology of cancer. Nat Rev Clin Oncol 7: 251-265.
18. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, Malik S, Pan F, Noushmehr H, van Dijk CM, et al. 2012. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res (this issue). doi: 10.1101/gr.117523.110.
19. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, et al., ed. 2011. SEER Cancer Statistics Review, 1975-2008. National Cancer Institute, Bethesda, MD. http://seer.cancer. gov/csr/1975-2008/ (based on November 2010 SEER data submission, posted to the SEER web site, 2011).
20. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, et al. 2011. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 10: 558-565.
21. Jensen JD, Laenkholm AV, Knoop A, Ewertz M, Bandaru R, Liu W, Hackl W, Barrett JC, Gardner H. 2011. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 17: 667-677.
22. Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, et al. 2012. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res (this issue) doi: 10.1101/gr.126573.111.
23. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, et al. 2009. Prognostic impact of discordance between triple-receptormeasurements in primary and recurrent breast cancer. Ann Oncol 20: 1953-1958.
24. Liegl-Atzwanger B, Fletcher JA, Fletcher CD. 2010. Gastrointestinal stromal tumors. Virchows Arch 456: 111-127.
25. Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A, Yang J, Semaan DJ, Chen C, Fox EA, et al. 2011. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med 17: 1116-1120.
26. Lord CJ, Ashworth A. 2008. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 8: 363-369.
27. Macconaill LE, Garraway LA. 2010. Clinical implications of the cancer genome. J Clin Oncol 28: 5219-5228.
28. Mangala LS, Han HD, Lopez-Berestein G, Sood AK. 2009. Liposomal siRNA for ovarian cancer. Methods Mol Biol 555: 29-42.
29. Olive KP, Tuveson DA. 2006. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 12: 5277-5287. (Pubitemid 44497240)
30. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al. 2005. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681. (Pubitemid 40825512)
31. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500. (Pubitemid 38720929)
32. Quintás-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P. 2008. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 5: 737-740.
33. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, et al. 2011. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 3: 111ra121. doi: 10.1126/scitranslmed.3003161.
34. Shaw JA, Page K, Blighe K, Hava N, Guttery D, Ward B, Brown J, Ruangpratheep C, Stebbing J, Payne R, et al. 2012. Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res (this issue). doi: 10.1101/gr.123497.111.
35. Thompson JF, Reifenberger JG, Giladi E, Kerouac K, Gill J, Hansen E, Kahvejian A, Kapranov P, Knope T, Lipson D, et al. 2012. Single-step capture and sequencing of natural DNA for detection of BRCA1 mutations. Genome Res (this issue). doi: 10.1101/gr.122192.111.
36. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Fu S, Piha-Paul SA, Naing A, Falchook GS, Janku F, Luthra R, et al. 2011. Personalized medicine in a phase I clinical trials program: The M.D. Anderson Cancer Center Initiative. J Clin Oncol 29: abstract CRA2500.
37. Turajlic S, Furney SJ, Lambros MB, Mitsopoulos C, Kozarewa I, Geyer FC, MacKay A, Hakas J, Zvelebil M, Lord C, et al. 2012. Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res (this issue). doi: 10.1101/gr.125591.111.
38. Vandin F, Upfal E, Raphael BJ. 2012. De novo discovery of mutated driver pathways in cancer. Genome Res (this issue). doi: 10.1101/gr.120477.111.
39. Verdine GL, Walensky LD. 2007. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin Cancer Res 13: 7264-7270.
40. Wagle N, Berger MF, Davis MJ, Blumenstiel B, DeFelice M, Pochanard P, Ducar M, Van Hummelen P, MacConaill LE, Hahn WC, et al. 2011. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discovery doi: 10.1158/2159-8290.
41. Wang L, Tsutsumi S, Kawaguchi T, Nagasaki K, Tatsuno K, Yamamoto S, Sang F, Sonoda K, Sugawara M, Saiura A, et al. 2012. Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. Genome Res (this issue). doi: 10.1101/gr.123109.111.
42. Weidle UH, Maisel D, Eick D. 2011. Synthetic lethality-based targets for discovery of new cancer therapeutics. Cancer Genomics Proteomics 8: 159-171.
43. Weinstein IB. 2002. Addiction to oncogenes-the Achilles heal of cancer. Science 297: 63-64. (Pubitemid 34743088)
44. Xiong Q, Ancona N, Hauser ER, Mukherjee S, Furey TS. 2012. Integrating genetic and gene expression evidence into genome-wide association analysis of gene sets. Genome Res (this issue). doi: 10.1101/gr.124370.111.
45. Xu Y, Hu B, Choi AJ, Gopalan B, Lee BH, Kalady MF, Church JM, Ting AH. 2012. Unique DNA methylome profiles in CpG island methylator phenotype colon cancers. Genome Res (this issue). doi: 10.1101/gr.122788.111.